Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride.
about
Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy.Current status of theranostics in prostate cancer.It is time to move forward into the era of Theranostics.Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches.PSMA Theranostics: Current Status and Future Directions.
P2860
Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride.
description
2017 nî lūn-bûn
@nan
2017 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Radioligand therapy of metasta ...... exposure to 223Ra-dichloride.
@ast
Radioligand therapy of metasta ...... exposure to 223Ra-dichloride.
@en
type
label
Radioligand therapy of metasta ...... exposure to 223Ra-dichloride.
@ast
Radioligand therapy of metasta ...... exposure to 223Ra-dichloride.
@en
prefLabel
Radioligand therapy of metasta ...... exposure to 223Ra-dichloride.
@ast
Radioligand therapy of metasta ...... exposure to 223Ra-dichloride.
@en
P2093
P2860
P356
P1433
P1476
Radioligand therapy of metasta ...... n exposure to 223Ra-dichloride
@en
P2093
Elisabeth Eppard
Florian C Gaertner
Markus Essler
Rolf Fimmers
Stefan Hauser
Stefan Kürpig
Stefanie Zimbelmann
P2860
P304
55567-55574
P356
10.18632/ONCOTARGET.15698
P407
P577
2017-02-25T00:00:00Z